Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.


Clinical Trial Description

Subjects will be enrolled in the study for a maximum of 43 days, including an optional 14-day screening period, 28 days of active product administration, and followed by a post-treatment follow-up within 1 day. The primary objective of this study is: - To evaluate the safety of PG-DN-20WS for the treatment of painful DPN of the feet compared to a placebo control, including emergence of suicidal thoughts. The secondary objectives of this study are: - To evaluate the impact of PG-DN-20WS on subject's neuropathic pain, anxiety, and sleep quality compared to a placebo control. - To evaluate the impact of PG-DN-20WS on the subject's impression of their response to the treatment compared to a placebo control. ;


Study Design


Related Conditions & MeSH terms

  • Diabetic Peripheral Neuropathic Pain
  • Neuralgia
  • Peripheral Nervous System Diseases

NCT number NCT04679545
Study type Interventional
Source Pure Green
Contact Matthew Caloura
Phone (248) 802-4380
Email mcaloura@pgpharma.co
Status Recruiting
Phase Phase 2
Start date December 10, 2020
Completion date April 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT04094662 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain Phase 3
Not yet recruiting NCT06054087 - Effectiveness of Electroacupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Not yet recruiting NCT05292066 - Efficacy of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain at Variable Dose Early Phase 1
Completed NCT04688671 - Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain Phase 2
Recruiting NCT06203002 - A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Phase 2
Completed NCT05620576 - A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05) Phase 2
Completed NCT04146896 - Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) Phase 2
Recruiting NCT05521737 - Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy N/A
Terminated NCT04707157 - Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Terminated NCT02156336 - Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP) Phase 4
Recruiting NCT06122012 - To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China N/A
Recruiting NCT06221241 - Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT01314222 - Diabetic Peripheral Neuropathic Pain (DPNP) Phase 2
Completed NCT00829387 - Cognitive Behavioral Therapy for Diabetic Neuropathic Pain N/A
Not yet recruiting NCT05766969 - Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA Phase 1/Phase 2
Completed NCT05349357 - Slider Versus Tensioner Neural Mobilization in Diabetic Peripheral Neuropathy N/A
Completed NCT03909841 - Neuropathic Pain in Elderly People With Diabetes: Impact on Quality of Life and Cognition
Completed NCT04476108 - Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Not yet recruiting NCT04953221 - The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain.
Completed NCT05177094 - Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2